Correlation between the concentrations of tumor necrosis factor-α and the severity of disease in patients infected with Orientia tsutsugamushi  by Iwasaki, Hiromichi et al.
International Journal of Infectious Diseases 14 (2010) e328–e333Correlation between the concentrations of tumor necrosis factor-a and the
severity of disease in patients infected with Orientia tsutsugamushi
Hiromichi Iwasaki a,*, Jiro Mizoguchi b, Nobuhiro Takada c, Katsunori Tai c, Satoshi Ikegaya a,
Takanori Ueda a
a First Department of Internal Medicine, Faculty of Medical Science, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Fukui 910-1193, Japan
b Educational Developmental Center for Local Medicine, Tohoku University School of Medicine, Sendai, Japan
cDepartment of Immunology and Medical Zoology, Faculty of Medical Science, University of Fukui, Fukui, Japan
A R T I C L E I N F O
Article history:
Received 27 March 2009
Received in revised form 31 May 2009
Accepted 1 June 2009
Corresponding Editor: Sunit K. Singh,
Hyderabad, India
Keywords:
Hypercytokinemia
Orientia tsutsugamushi
Tetracycline
Tumor necrosis factor-a
Interleukin-10
A B S T R A C T
Background: Patients with tsutsugamushi disease sometimes die if they do not receive appropriate
chemotherapy. This study measured the concentration of several cytokines both before and after the
administration of tetracyclines, and evaluated the changes in cytokine levels in patient serum to
investigate the relationship between serum levels of cytokines and disease severity.
Methods: A total of nine patients were infected with Orientia tsutsugamushi. The diagnosis of
tsutsugamushi disease was made using an indirect immunoperoxidase antibody test. The serum
concentrations of cytokines were measured using enzyme-linked immunosorbent assays.
Results: The levels of interleukin (IL)-10 (mean 71.7 pg/ml) and IL-12p40 (mean 588 pg/ml) were
elevated in all patients in the acute phase, above the normal upper limits. Tumor necrosis factor-a (TNF-
a) levels (mean 9.20 pg/ml) were elevated in 89% and interferon-g (IFN-g) levels (mean 41.0 pg/ml) in
44% of patients. The down-regulation of these overproduced cytokines was observed after
chemotherapy. There was a signiﬁcant correlation between the concentrations of TNF-a in the acute
phase and the severity of disease (r = 0.918).
Conclusion: The concentration of TNF-amay predict the severity of tsutsugamushi disease in the acute
infectious phase.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infection with Orientia tsutsugamushi occurs frequently in
Southeast Asia; this infection is called mite-borne typhus or scrub
typhus and also tsutsugamushi disease. The etiologic agent of
tsutsugamushi disease was previously known as Rickettsia
tsutsugamushi.1,2 Because of phenotypic and genotypic differences
between this pathogen and other species belonging to the genus
Rickettsia, the genus Orientia was proposed for this pathogen.3
Serum antigenic serotypes of O. tsutsugamushi have been reported
to differ in their virulence in experimental animals.4 Gilliam, Karp,
and Kato are highly virulent strains, and they can spread to become
severe and potentially life-threatening.5,6 However, other anti-
genic serotypes, such as Shimokoshi, Kawasaki, Kuroki, and others,
have also recently been described.7–10 The vector of this infectious
disease is the trombiculid mite, named tsutsugamushi, which is
distributed in mountainous areas and around rivers throughout* Corresponding author. Tel.: +81 776 61 8344; fax: +81 776 61 8109.
E-mail address: hiwasaki@u-fukui.ac.jp (H. Iwasaki).
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coincide with areas that are routinely used by human beings such
as farmers, woodcutters, and hikers.
Recently, almost 500 patients per year have been reported with
tsutsugamushi disease in Japan. Tsutsugamushi disease is char-
acterized by fever, rash, and eschar, and is sometimes complicated
with pneumonia, meningitis, disseminated intravascular coagula-
tion (DIC), and systemic inﬂammatory response syndrome
(SIRS),11 leading to severe multiorgan failure if patients do not
receive appropriate treatment. It has been recognized that SIRS is
associated with an exacerbated production of cytokines,12 and
fulminant cases of tsutsugamushi disease have also been found to
show hypercytokinemia.2,13
It is well known among physicians that tetracyclines are very
effective against tsutsugamushi disease, and a majority of patients
show dramatic defervescence within 24 h after starting anti-
rickettsial chemotherapy using tetracyclines, although the
mechanism of this dramatic effect is still unknown.1 Therapeutic
approaches directed against various components of the inﬂam-
matory processes such as down-regulation of the immune
response by inﬂammatory cell apoptosis, inhibition of matrixses. Published by Elsevier Ltd. All rights reserved.
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ﬂammatory cytokines, could offer more effective treatments.
Therefore, tetracyclines may not only have an antimicrobial
function but also anti-inﬂammatory properties in various dis-
orders.15–17 This study measured the concentration of several
cytokines both before and after the administration of tetracyclines,
and evaluated changes in cytokine levels in patient serum.
2. Materials and methods
2.1. Patients
The present study investigated nine Japanese patients with
conﬁrmed O. tsutsugamushi infection between 1998 and 2005, to
determine changes in serum cytokine levels. All patients lived in
Yamagata Prefecture, in the north of Honshu, Japan. Each of these
patients required intensive treatment in hospital to control
symptoms and complications. Every patient responded well to
treatment with tetracyclines for 2 weeks (one patient was
administered doxycycline 200 mg/day and the others were
administered minocycline 200 mg/day). A diagnosis of tsutsuga-
mushi disease was made upon determination of a four-fold rise in
IgG antibody titer to strains of O. tsutsugamushi (Gilliam or Karp
serotype) in serum, as detected by an indirect immunoperoxidase
antibody test18 performed on paired serum samples collected
during the acute and convalescent phases. No patient had an
autoimmune disease or was in an immunocompromised state
before this infectious episode happened.
2.2. Clinical severity scoring system
To evaluate the severity of tsutsugamushi disease, severity
scores were used as reported previously.13 In brief, the score was
calculated as the sum of different point values assigned to speciﬁc
criteria: central nervous system involvement, severe myalgia,
radiographically documented pulmonary involvement, renal or
liver dysfunction, hepatosplenomegaly, and DIC (Table 1).
2.3. Cytokine measurement
Serum levels of tumor necrosis factor-a (TNF-a) and inter-
leukin (IL)-12p40 as proinﬂammatory cytokines, IL-10 as an anti-
inﬂammatory cytokine, interferon-g (IFN-g) as a Th1 cytokine, and
IL-4 as a Th2 cytokine, were measured using an enzyme-linked
immunosorbent assay kit (Cytoscreen, Biosource, Camarillo, CA,
USA). The amount of cytokine in each sample was determined by
comparison with a standard curve. Data are reported as theTable 1
Clinical severity scoring system
Central nervous system involvement 1
Severe myalgia 1
Radiographically documented pulmonary involvement 1
Elevated serum creatinine level:
1.5–3.5 mg/dl 1
>3.5 mg/dl 2
Elevated serum ALT level:
41–100 IU/l 1
>100 IU/l 2
Hepatosplenomegaly 1
Thrombocytopenia with platelet count:
100–149109/l 1
<100109/l 2
Elevated level of FDP 1
ALT, alanine aminotransferase; FDP, ﬁbrin/ﬁbrinogen degradation products.
The score was calculated as the sum of different point values assigned to speciﬁc
criteria. These scores, with possible total points ranging from 0 to 11, were
determined on the basis of laboratory data and major symptoms on admission.concentrations of each cytokine in the acute and convalescent
phases. Sera were frozen within 8 h of being received and were
stored at  80 8C until analysis. In our experience, freezing had no
inﬂuence on the results on retesting. Serum cytokine levels in the
nine patients were determined routinely on admission in the acute
phase; moreover they were also measured 2 weeks after the
initiation of anti-rickettsial chemotherapy, i.e., in the convalescent
phase. We adopted the values that were determined in normal
subjects from eight through 23 samples in the protocols for each
cytokine measurement as normal values.
2.4. Statistical analyses
Analysis of the correlation between the clinical severity score
and cytokine levels in acute phase serum of patients was
performed, and the paired Student’s t-test was used for statistical
analyses using statistical software (Microsoft Excel 2003). A
comparison was considered statistically signiﬁcant if the p-value
was <0.05. This study was approved by the Institutional Review
Board of the Faculty of Medical Science of the University of Fukui.
3. Results
3.1. Proﬁles, symptoms, and laboratory data of nine patients with
tsutsugamushi disease
Patient characteristics are shown in Tables 2 and 3. Each patient
exhibited a persistent fever above 38.0 8C and eschar, a character-
istic site for a mite bite, where the pathogen was inoculated.
Laboratory data showed that alanine aminotransferase (ALT)
increased more than 40 IU/l in 89% (8/9) of patients and
lymphadenopathy was detected in 56% (5/9) of patients. Some
patients had severe complications: DIC, meningeal symptoms, and
severe myalgia. Severity scores, with possible total points ranging
from 0 to 11, were determined on the basis of laboratory data and
major symptoms on admission. The median score for the nine
patients in this study on admission was 4 (range 2–6; mean 
standard deviation 3.9  1.5). The rationale for using this scoring
system was to ensure that the increased complexity of disease in
patients not currently being treated was consistently represented in
evaluations and descriptions. The patients were separated into two
groups. Onewas a higher severity score group that showed a score5,
and the other was a lower severity score group with a score<5. Three
patients belonged to the higher severity score group, and six patients
belonged to the lower severity score group. The mean scores of the
higher and lower severity groups were 5.7 and 3.0, respectively.
The IgG antibody titers were more than 1:320 during the
clinical phase of each patient, and IgM antibody titers also
increased. Only one patient was diagnosed with Gilliam serotype
infection, the others were diagnosed as Karp serotype infection
(Table 3).
3.2. Cytokine levels in serum during anti-rickettsial treatment of
patients with tsutsugamushi disease
The serum levels of IL-10 (normal range <3.2 pg/ml) and IL-
12p40 (normal range <3.2 pg/ml) were elevated in all patients,
above the normal limits, during the acute phase of the disease.
Serum TNF-a levels were elevated above the normal upper limit
(0.12 pg/ml) in 89% (8/9) of patients, and IFN-g levels were
elevated above the normal level (20.9 pg/ml) in 44% (4/9) of
patients. The levels of these four cytokines decreased signiﬁcantly
in the convalescent phase (Figures 1–3). However, IL-4 did not
show any changes in either the acute or convalescent phases
(Figure 3). The mean concentrations of IFN-g, IL-4, IL-10, IL-12p40,
and TNF-a in serum from the higher and lower severity score
Table 2
Proﬁles and symptoms of patients with tsutsugamushi disease
Pt No. Age Sex Eschar Lymphadenopathy Clinical daya Severity score Severe complications
1 63 M + + 9 2
2 52 M + + 1 4
3 73 M +  10 2
4 64 F + + 7 6 DIC
5 68 M + + 5 3
6 74 M + + 16 5 Meningeal symptoms, severe myalgia
7 84 F +  5 3
8 75 F +  6 4 DIC
9 67 F +  7 6 DIC, meningeal symptoms
DIC, disseminated intravascular coagulation.
a Clinical day: the day fever appeared was assigned as the day of onset, and clinical days indicate the days after onset.
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shown in Table 4.
A correlation between the severity of tsutsugamushi disease
and serum concentrations of TNF-a in the acute phase was veriﬁed
(r = 0.918, Figure 4). The cases with high TNF-a levels (over 18 pg/
ml) showed high severity scores of 5. The concentrations of TNF-
a in the patients in the higher severity score group (score5) were
signiﬁcantly higher than those of the lower severity score group
(score <5) in the acute phase (p = 0.006, Table 4). The concentra-
tions of TNF-a in serum of convalescent phase patients were
signiﬁcantly (p = 0.023) decreased compared with the acute phase
(Figure 1). The correlation between serum concentrations of TNF-a
and IL-10 in the acute phase was not veriﬁed (r = 0.534, data not
shown).
4. Discussion
Patients with tsutsugamushi disease sometimes suffer from
severe clinical complications in the absence of appropriate anti-
microbiological chemotherapy. The precise mechanism leading to
such severe complications is not well understood. It has been
reported that an innate anti-inﬂammatory cytokine proﬁle may
contribute to fatal bacterial infectious disease.19 The inﬂamma-
tion-related cytokine response is an initial and essential host
response to an infectious challenge. However, when excessive, the
inﬂammatory response leads to harmful, or even fatal, conse-
quences, as seen in septic shock or multiple organ failure. Recently
the concept of SIRS has been proposed.11 SIRS can occur in patients
with various inﬂammatory disorders, not only infection, including
pancreatitis, ischemia, multiple trauma, hemorrhagic shock, and
immunologically mediated organ injury.11 In a life-threateningTable 3
Laboratory data for patients with tsutsugamushi disease
Pt No. WBC
( 109/l)
PLT
( 109/l)
ALT
(IU/l)
Antibody titera Serotype of
O. tsutsugamushi
Acute
phase
Convalescent
phase
1 6.9 137 51 <1:10 1:320 Gilliam
2 2.7 97 148 <1:10 1:1280 Karp
3 3.9 67 307 1:40 1:1280 Karp
4 5.0 46 118 1:80 1:10240 Karp
5 6.9 137 364 1:320 1:20480 Karp
6 6.3 178 61 1:40 1:2560 Karp
7 5.6 52 45 1:40 1:2560 Karp
8 5.0 110 40 <1:10 1:5120 Karp
9 9.8 110 68 <1:10 1:640 Karp
WBC, white blood cell count; PLT, platelet count; ALT, alanine aminotransferase.
a A diagnosis of tsutsugamushi disease was made upon determination of a four-
fold rise in IgG antibody titer against O. tsutsugamushi (Gilliam or Karp serotype) in
serum as detected by an indirect immunoperoxidase assay performed on paired
serum samples collected during the acute and convalescent phases. The titers
indicated here were maximums during the clinical course.infection, the systemic release of numerous cytokines is not
properly regulated, and higher serum concentrations of inﬂam-
matory cytokines have been strongly implicated in the develop-
ment of SIRS.20 For instance, it has also been suggested that
hyperproduction of chemokines and cytokines is associated with
susceptibility during O. tsutsugamushi infection in susceptible and
resistant mice models.21 Other studies on TNF-a in animal and
human models have indicated a protective role of this cytokine
during infection.22,23 In contrast, some studies have demonstrated
a fatal role of TNF-a in the pathogenesis of various infectious
diseases.24–26 Because TNF-a is essential for host defense, under-
production of TNF-a may help the proliferation of the pathogen;
however, over-production of TNF-amay be harmful to the host. In
the present study, the concentration of TNF-a in the serumof acute
phase patients with tsutsugamushi disease increased, and the
highest level was 29.3 pg/ml. Moreover, the serum levels of TNF-a
have a relationshipwith the severity of tsutsugamushi disease. The
TNF-a levels in the acute phase could predict the severity of this
infectious disease.
TNF-a is a decisive proinﬂammatory cytokine in the host’s
response to infection, and IL-10 is an anti-inﬂammatory cytokineFigure 1. Changes in inﬂammatory cytokine TNF-a levels in serum during anti-
rickettsial treatment of patients with tsutsugamushi disease. A: acute phase, B:
convalescent phase.
Figure 2. The concentrations of IL-10 and IL-12p40 in serum samples, both in the acute and convalescent phases of patients with tsutsugamushi disease. A: acute phase, B:
convalescent phase.
Figure 3. The concentrations of INF-g and IL-4 in serum samples, both in the acute and convalescent phases of patients with tsutsugamushi disease. A: acute phase, B:
convalescent phase.
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imbalance of these two cytokines, with low levels of TNF-a and
high levels of IL-10, may be important in the deteriorating
condition of patients with bacterial infections.19,27 These cytokines
that regulate inﬂammation should be maintained at appropriate
concentrations after anti-microbiological chemotherapy. IL-10 is
also an inhibitor of monocyte/macrophage activation, blocking the
expression of TNF-a and other proinﬂammatory mediators. In this
study, every patient showed high serum levels of IL-10 in the acute
phase. It has previously been reported that IL-10-deﬁcient mice
produce enhanced amounts of TNF-a in response to lipopolysac-
charide (LPS).28 Moreover it was hypothesized that IL-10 functions
as a temporal regulator of the transition from early reversiblesepsis to the late phase of irreversible shock in the sepsis model.29
However, the molecular pathways by which IL-10 inhibits TNF-a
production are unclear, with diverse mechanisms having been
published.30 A clear relationship between TNF-a and IL-10was not
obtained in this study of tsutsugamushi disease. A full under-
standing of the mechanism for the post-transcriptional regulation
of TNF-a by IL-10 in human cells will obviously require a more
extensive study and may require the discovery of as yet unknown
pathways involved in the general post-transcriptional control of
this gene.
In the early stage of the acute phase of tsutsugamushi disease,
excessive levels of Th1 effecter cytokines, such as IFN-g and IL-12,
have been indicated. IL-12 has a pivotal role in the Th1-mediated
Table 4
Mean concentrations (pg/ml) of ﬁve different cytokines in sera of higher and lower
severity score group patients with tsutsugamushi disease in the acute phase
Cytokine Severity
score 5
Severity
score <5
Total Normal range
IFN-g 52.031.3 35.575.3 41.00.99 <20.9
IL-4 1.691.71 0.790.89 1.091.11 <6.0
IL-10 10459.4 55.449.2 71.75.01 <3.2
IL-12p40 578278 593162 588186 <3.2
TNF-aa 24.05.28 1.792.32 9.2011.6 <0.12
IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
Cytokine concentrations (mean SD) were measured using ELISA. The limits of assay
sensitivity were as follows: 0.09 pg/ml for TNF-a, 0.78 pg/ml for IL-10, 0.27 pg/ml for
IL-4, 0.8 pg/ml for IL-12p40, and 2.0 pg/ml for IFN-g.
a p<0.05 was used as the criterion of signiﬁcance.
Figure 4. Relationship between the clinical score and the levels of TNF-a in the
acute phase serum of patients with tsutsugamushi disease: r = 0.918.
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subunits (p40 and p35), is produced by antigen-presenting cells
(phagocytes and dendritic cells), and targets natural killer and the
T cells inducing the production of IFN-g.31–34 However, IL-4, which
is a Th2 cytokine, did not show a signiﬁcant response during the
symptomatic phase of the illness. It is still unknown whether the
balance between Th1 and Th2 is affected by the progress of acute
rickettsial infection, whereas the cytokine proﬁles of patients with
tsutsugamushi disease demonstrated strong Th1 responses
characterized by an increase in IFN-g in the early acute phase.
The improvement of representative symptoms, including fever,
after the administration of tetracyclines was shown in the early
period, sometimes within 24 h, in almost all patients with
tsutsugamushi disease, despite the presence of O. tsutsugamushi
DNA in peripheral blood mononuclear cells of the patients.35
O. tsutsugamushi DNA was present in peripheral blood until day 3–
8 after the initiation of treatment with tetracyclines.35 Whereas
PCR detection of rickettsial DNA does not mean the existence of
live organisms, this microbiological structure still activates the
host immunological responses. Therefore, prompt clinical
improvement may not depend on the eradication of the pathogen
rather on the cessation of over-production of cytokines as a result
of treatment with tetracyclines. Recently signiﬁcantly higher
concentrations of proinﬂammatory cytokines during the acute
phase of tsutsugamushi disease have been reported by other
investigators,36 as well as the marked decrease of cytokines
including TNF-a, IFN-g and IL-10 detected after starting doxycy-
cline.37 Tetracyclines may have the potential to reduce the
overproduction of these cytokines and to release a patient from
hypercytokinemia induced by O. tsutsugamushi infection as
described in Cazalis’ study, which showed that tetracyclines
modulate cytokine secretion by LPS-stimulated whole blood.38These phenomena may indicate that tetracyclines have an
important role in the modulation of cytokine levels or hypercy-
tokinemia derived from rickettsial infection.
In conclusion, TNF-a, IFN-g, IL-10, and IL-12p40 levels
increased in the serum of patients with tsutsugamushi disease
during the acute phase. Similar results were reported for other
kinds of rickettsial infection, such as Japanese spotted fever caused
by infection with Rickettsia japonica.39 The concentration of the
proinﬂammatory cytokine TNF-a in the acute phase predicted the
severity of tsutsugamushi disease. If febrile patients are suspected
of having tsutsugamushi disease, as revealed by the high
concentration of TNF-a that is not speciﬁc for this infectious
disease, they should be administered tetracyclines and placed
under strict management.
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